<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Ophthalmol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Ophthalmology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Ophthalmol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2674-0826</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fopht.2026.1758717</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Mini Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Periocular necrotizing fasciitis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Somani</surname><given-names>Zaynab</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname><given-names>Hyun Jun</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Harrison</surname><given-names>Andrew</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Mokhtarzadeh</surname><given-names>Ali</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1463995/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>University of Minnesota Medical School</institution>, <city>Minneapolis</city>, <state>MN</state>,&#xa0;<country country="us">United States</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Ophthalmology and Visual Neurosciences, University of Minnesota</institution>, <city>Minneapolis</city>, <state>MN</state>,&#xa0;<country country="us">United States</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Otolaryngology and Head and Neck Surgery, University of Minnesota</institution>, <city>Minneapolis</city>, <state>MN</state>,&#xa0;<country country="us">United States</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Ali Mokhtarzadeh, <email xlink:href="mailto:mokh0003@umn.edu">mokh0003@umn.edu</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-26">
<day>26</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>6</volume>
<elocation-id>1758717</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>12</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Somani, Kim, Harrison and Mokhtarzadeh.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Somani, Kim, Harrison and Mokhtarzadeh</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-26">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Necrotizing fasciitis is a rapidly progressive infection commonly associated with group A <italic>Streptococci</italic> and other toxin-producing bacteria that leads to microvascular thrombosis, tissue ischemia, and fascial plane spread. Although the periorbital region&#x2019;s rich vascularity and natural anatomic barriers help limit deep extension and systemic spread, periorbital necrotizing fasciitis (PNF) can cause septicemia, systemic toxicity, and death. Early diagnosis is critical but remains challenging; distinguishing PNF from inflammatory mimics such as Sweet&#x2019;s syndrome is critical given their opposing interventions. Surgical debridement along with intravenous antibiotics remain the cornerstone of treatment. However, considering the significant morbidity from vision loss and disfigurement, the decision to pursue early surgical debridement versus conservative management remains an area of active debate. Emerging blood biomarkers may aid diagnosis, and adjunctive therapies, including hypochlorous irrigation, show promise in improving outcomes of PNF while minimizing treatment-associated morbidities. This mini-review synthesizes current treatment evidence for PNF, integrating findings from PNF-focused literature and studies of generalized-NF at other anatomical sites. While principles utilized in the treatment of generalized NF may be applicable to PNF, exact statistics may vary by anatomic site.</p>
</abstract>
<kwd-group>
<kwd>eyelid cellulitis</kwd>
<kwd>eyelid necrotizing fasciitis</kwd>
<kwd>necrotizing fasciitis</kwd>
<kwd>orbital cellulites</kwd>
<kwd>orbital infections</kwd>
<kwd>orbital necrotizing fasciitis</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was not received for this work and/or its publication.</funding-statement>
</funding-group>
<counts>
<fig-count count="0"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="35"/>
<page-count count="7"/>
<word-count count="3632"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Oculoplastics, Orbit and Trauma</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Necrotizing fasciitis (NF) is life-threatening bacterial infection characterized by extensive necrosis of superficial fascia (<xref ref-type="bibr" rid="B1">1</xref>) with rapid progression along subcutaneous soft tissue planes. The widespread bacterial load of this infection, often caused by group A <italic>&#x3b2;</italic>-hemolytic <italic>Streptococci (GABHS), Staphylococcus Aureus</italic>, the <italic>Clostridium</italic> species, <italic>Vibrio vulnifuncus</italic>, and other toxin-producing bacteria may result in septic shock (<xref ref-type="bibr" rid="B1">1</xref>). Although NF most frequently involves the groin, abdomen, and lower extremities, it can rarely affect the head and neck, including the periorbital region. Despite the robust vascular supply, periorbital necrotizing fasciitis (PNF) carries a high risk of vision loss, systemic complications, and mortality due to potential extension to the cervical viscera and thoracic cavity (<xref ref-type="bibr" rid="B2">2</xref>). Prompt diagnosis and treatment are critical to improving visual and survival outcomes. This review encompasses risk factors, pathogenesis, clinical presentation, diagnostic features, and management of PNF cases over the past 30 years.</p>
</sec>
<sec id="s2">
<title>Epidemiology</title>
<p>While comprehensive epidemiologic data for all bacterial causes of NF are limited, life-threatening <italic>GABHS</italic> infections, including NF, toxic shock syndrome, and bacteremia, occur at an incidence of 3 per 100,000 individuals annually in the United States (<xref ref-type="bibr" rid="B3">3</xref>). NF itself remains a rare but rapidly progressive infection, with an estimated incidence of 0.4 per 100,000 individuals annually in the United States, corresponding to 10,000 cases annually (<xref ref-type="bibr" rid="B4">4</xref>). Approximately 10% of NF cases involve the head and neck region, with orbital and periorbital involvement comprising a small subset. One retrospective review identified 58 well-documented case records of PNF over a fifty-year period (<xref ref-type="bibr" rid="B5">5</xref>). PNF occurs predominately in adults, with a median age of 46.3 years (<xref ref-type="bibr" rid="B6">6</xref>) with incidence increasing markedly after age 80, and mortality increasing after age 50 (<xref ref-type="bibr" rid="B7">7</xref>).</p>
<p>Risk factors for NF include diabetes mellitus, chronic renal failure, cardiovascular disease, peripheral vascular disease, rheumatologic disease, drug misuse, alcoholism, malignancy, and immunocompromise (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B8">8</xref>&#x2013;<xref ref-type="bibr" rid="B11">11</xref>). Disease progression to shock and multi-organ failure has been associated with unidentified body punctures, pressure ulcers in immobilized patients, and delayed medical treatment (<xref ref-type="bibr" rid="B12">12</xref>).</p>
<p>The most common precipitating events for PNF are penetrating or surgical traumas, such as blepharoplasty, dacryocystorhinostomy (<xref ref-type="bibr" rid="B6">6</xref>), and minor traumas including insect bites (<xref ref-type="bibr" rid="B6">6</xref>). Adjacent infections from dacryocystitis, sinusitis, pneumonia, and parotid gland infections have also been implicated (<xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>Notably, up to 52% of patients with NF have no identifiable comorbidities or predisposing factors (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B13">13</xref>).</p>
</sec>
<sec id="s3">
<title>Pathogenesis</title>
<p>NF derives its title from the rapid spread of necrosis through fascial planes. Based on microbiologic etiology agents, NF is classified into four types (<xref ref-type="bibr" rid="B10">10</xref>). Type I is polymicrobial, typically involving <italic>Streptococcus</italic> species, <italic>Klebsiella</italic> species, <italic>S. aureus</italic>, and <italic>E. coli.</italic> Type II is monomicrobial and most commonly caused by <italic>GABHS</italic> with or without concurrent <italic>S. aureus</italic>. Type III, albeit rare, is associated with marine Gram-negative pathogens including <italic>Vibrio vulnifuncus</italic> and <italic>Clostridium</italic> species. Type IV is fungi in origin, most often involving <italic>Apophysomyces</italic> and <italic>Aspergillus</italic>, and is associated with uncontrolled diabetes (<xref ref-type="bibr" rid="B10">10</xref>). Types II, III, and IV have been documented in PNF, with <italic>GABHS</italic> and <italic>S. aureus</italic> representing the most common causative organisms (<xref ref-type="bibr" rid="B10">10</xref>).</p>
<p>Periorbital involvement is uncommon due to its distinct natural anatomic barriers. The orbital septum, orbicularis oculi muscle, firm dermal attachments at the nasojugal and malar folds, and a robust vascular supply limit bacterial penetration into deeper fascial layers (<xref ref-type="bibr" rid="B10">10</xref>) and reduce the risk of superficial infection.</p>
<p>As such, mechanical damage to the skin as an entry point for inoculation is the most frequent instigator of PNF. After the dermal and muscular barriers are compromised, principal pathogens produce exotoxins driving necrosis and their spread into the orbital apex, throat, and systemic circulation (<xref ref-type="bibr" rid="B10">10</xref>). In Type II <italic>GABHS</italic>-predominant NF, superantigens including streptococcal pyrogenic exotoxins (Spe) A and C, in addition to Staphylococcal TSST-1 and enterotoxins (<xref ref-type="bibr" rid="B11">11</xref>), induce widespread T-cell activation while bypassing antigen specificity. Simultaneously, the streptococcal protease and virulence factors blunt the neutrophilic and phagocytic response needed for an effective antibacterial response. The resulting pro-inflammatory cytokine surge results in endothelial dysfunction and platelet aggregation (<xref ref-type="bibr" rid="B10">10</xref>). Resulting microvasculature thrombosis restricts immune cell trafficking and antibiotic penetration, facilitating horizontal infectious spread along fascial planes (<xref ref-type="bibr" rid="B14">14</xref>), ultimately leading to further ischemia, bullae formation, ulceration, necrosis (<xref ref-type="bibr" rid="B15">15</xref>), and toxin release. In Type I polymicrobial NF, Gram-negative organisms produce endotoxins and LPS-mediated inflammation, while Type III pathogens, including <italic>Vibrio vulnificus</italic> and <italic>Clostridium</italic> species, generate cytolysins and lecithinase-alpha toxins, yielding myonecrosis, hemolysis, and vascular injury (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). Bacterial hyaluronidase and collagenase can amplify the lateral extension of infection.</p>
</sec>
<sec id="s4">
<title>History, signs, and diagnosis</title>
<p>Early NF frequently follows small cutaneous insults such as insect bites or pressure ulcers. These are commonly misdiagnosed as cellulitis (<xref ref-type="bibr" rid="B12">12</xref>), resulting in diagnostic delays and progression to critical necrosis spreading to distal limbs (<xref ref-type="bibr" rid="B10">10</xref>).</p>
<p>Patients typically present with tense, erythematous periorbital skin (<xref ref-type="bibr" rid="B18">18</xref>), pain disproportionate to exam, and rapidly progressive edema that may cross fascial planes despite intact overlying skin (<xref ref-type="bibr" rid="B5">5</xref>). Systemic symptoms such as high fever, rigor, and sweating are common. Characteristic signs of PNF include bullae, violaceous-cyanotic discoloration with irregular erythematous borders, and gangrene that develop within 24 hours. Disease progression is rapid with frank cutaneous necrosis, anesthesia due cutaneous nerve destruction, and crepitus developing in 4&#x2013;5 days (<xref ref-type="bibr" rid="B6">6</xref>). Neutropenic patients may lack classic such inflammatory findings (<xref ref-type="bibr" rid="B6">6</xref>) necessitating higher diagnostic suspicion. Systemic toxicity-including fever, hypotension, hypothermia, and electrolyte derangements-is frequent (<xref ref-type="bibr" rid="B12">12</xref>). In contrast to NF affecting other regions, PNF frequently demonstrates bilateral involvement due to low resistance of subcutaneous tissue across the nasal bridge, facilitating infectious spread in up to 45% of cases (<xref ref-type="bibr" rid="B10">10</xref>).</p>
<p>Evaluation of PNF is challenging due to a number of diagnostic pitfalls, including orbital cellulitis (<xref ref-type="bibr" rid="B12">12</xref>), zoster, erysipelas, and angioedema (<xref ref-type="bibr" rid="B10">10</xref>). As a result such, early diagnosis is reportedly missed in 85 to 100 percent of cases (<xref ref-type="bibr" rid="B19">19</xref>). Diagnosis remains largely clinical but is supported by evidence of systemic inflammation, including elevated CRP (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B20">20</xref>), leukocytosis (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B21">21</xref>), and increased procalcitonin levels (<xref ref-type="bibr" rid="B20">20</xref>). Among these, leukocytosis has been identified as a particularly important indicator and may help differentiate NF from other soft-tissue infections (<xref ref-type="bibr" rid="B21">21</xref>) with sensitivities and specificities exceeding 90%. Routine laboratory parameters are incorporated into the Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score, which aids in early detection of NF, particularly in clinically equivocal presentations. A LRINEC score of &#x2265;6 should heighten clinical suspicion for NF (<xref ref-type="bibr" rid="B21">21</xref>). Readily available online calculators may serve as an adjunct to bedside risk stratification.</p>
<p>CT and MRI imaging may further support diagnosis by revealing fascial thickening, soft tissue gas, or extension into the orbitofacial compartments, helping distinguish NF from cellulitis or myonecrosis (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B22">22</xref>). While MRI is superior in localizing the initial infection site, a PNF case report found that CT may sufficiently guide surgical intervention (<xref ref-type="bibr" rid="B23">23</xref>). Aerobic and anerobic wound cultures are initiated prior to the administration of narrowed antibiotic therapy, and typically isolate polymicrobial flora including <italic>GABHS</italic> and <italic>S. aureus</italic>. Blood cultures are low in sensitivity and not well supported in literature (<xref ref-type="bibr" rid="B6">6</xref>). Frozen section biopsy can confirm facial necrosis, revealing dense collections of gram-positive cocci (<xref ref-type="bibr" rid="B6">6</xref>). Emerging hematologic indices such as the neutrophil-to-lymphocyte and neutrophil-to-platelet ratios show promise in differentiating PNF from orbital cellulitis (<xref ref-type="bibr" rid="B24">24</xref>).</p>
<p>Necrotizing Sweet&#x2019; syndrome, a rare neutrophilic dermatosis, may mimic NF clinically and radiographically. It&#x2019;s shared tender, erythematous presentation but opposing treatment presents a crucial diagnostic pitfall, making histopathologic evaluation (showcasing neutrophilic infiltrate without microorganisms) critical for distinction (<xref ref-type="bibr" rid="B25">25</xref>).</p>
</sec>
<sec id="s5">
<title>Treatment</title>
<p>PNF requires urgent intervention to reduce mortality and preserve ocular function. Prompt initiation of empiric broad-spectrum antibiotics is critical. Standard empiric PNF therapy should include &#x3b2;-lactams for streptococcal and gram-negative coverage, clindamycin to suppress toxin synthesis (<xref ref-type="bibr" rid="B5">5</xref>), and an aminoglycoside or metronidazole for polymicrobial or anaerobic coverage. Clindamycin should not be used as monotherapy due resistance concerns (<xref ref-type="bibr" rid="B6">6</xref>). Once culture data are available, therapy is narrowed accordingly. PNF&#x2019;s thrombotic character impedes antibiotic penetration to the site (<xref ref-type="bibr" rid="B6">6</xref>), supporting the frequent need for surgical debridement of the affected tissue in conjunction with antibiotic therapy.</p>
<p>Surgical debridement remains the cornerstone of PNF management. Early removal of necrotic tissue reduces bacterial load, toxin-mediated tissue injury, and tissue ischemia, while retaining as much healthy skin and orbital tissue as possible (<xref ref-type="bibr" rid="B5">5</xref>). However, the rich periocular vascular supply and functional morbidity with tissue loss allows clinicians to exercise clinical judgement. Some series advocate extensive debridement of subcutaneous tissue until vascularized tissue is encountered, with conservative excision of overlying skin (<xref ref-type="bibr" rid="B5">5</xref>). Other PNF series (<xref ref-type="bibr" rid="B26">26</xref>,&#xa0;<xref ref-type="bibr" rid="B27">27</xref>) support a tissue-sparing approach, particularly in patients with stable or improving inflammatory markers, involving selective removal of eschars and frank necrosis while allowing for granulation of junctional tissue (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). These findings suggest that aggressive early excision may not be universally required in PNF, in contrast to generalized NF, where an average of 3 debridements is often required for complete source control (<xref ref-type="bibr" rid="B12">12</xref>). Exenteration remains controversial, but may rarely be indicated when necrotizing inflammation spreads into the orbit (<xref ref-type="bibr" rid="B5">5</xref>).</p>
<p>Topical hypochlorous acid (0.01% HOCl) has emerged as a promising adjunct in NF for wound irrigation due to its anti-microbial, antitoxin, and antibiofilm activity with minimal host cytotoxicity (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B27">27</xref>). Flow-through delivery via vacuum-assisted closure (VAC) systems used in generalized-NF may be applicable for complex periocular cases (<xref ref-type="bibr" rid="B11">11</xref>). Additional adjunctive therapies, including intravenous immunoglobulin (IVIG) to neutralize toxin activity and hyperbaric oxygen to limit tissue ischemia, have been reported though robust clinical data supporting their routine use is lacking (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B10">10</xref>).</p>
</sec>
<sec id="s6">
<title>Management</title>
<p>Following debridement, wound care is essential for recovery. Contemporary protocols increasingly employ negative pressure wound therapy (NPWT), VAC systems, or vacuum sealing drainage (VSD) dressings to control wound exudate and promote granulation. A case series of generalized-NF utilized sized V.A.C. GranuFoam, V.A.C. VeraT.R.A.C, or V.A.C. VeraFlo dressings with flow-through HOCl irrigation (delivered through inflow tubes&#xa0;constructed from intravenous line extensions) sealed with&#xa0;Stomadhesive Paste and adhesive drape (<xref ref-type="bibr" rid="B11">11</xref>). Another retrospective analysis of generalized-NF described postoperative VSD with twice-daily irrigation containing insulin, lidocaine, and recombinant acidic fibroblast growth factor in saline solution to stimulate granulation (<xref ref-type="bibr" rid="B12">12</xref>).</p>
<p>PNF wound management emphasizes repeated debridement until all necrotic tissue is removed followed by irrigation with normal saline (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B10">10</xref>). Regular bedside dressing changes with non-adherent, moisture-retentive materials should be performed. The extent of tissue loss informs reconstruction. Delayed split- and full-thickness skin grafts are effective in management of postoperative lagophthalmos and ectropion. Large defects may require fasciocutaneous free flaps to restore eyelid function (<xref ref-type="bibr" rid="B7">7</xref>).</p>
</sec>
<sec id="s7">
<title>Association with COVID-19</title>
<p>Recent reports have described an increased incidence of head and neck NF during the COVID-19 pandemic, suggesting a potential association. One generalized-NF case series described higher post-pandemic case counts, an increased need for debridement, and 12.5% increased rate of mortality (<xref ref-type="bibr" rid="B28">28</xref>). Proposed explanations include pandemic-related delays in care and worsening glycemic control among diabetics as well as COVID-associated endothelial injury, hypercoagulability, and immune dysregulation (<xref ref-type="bibr" rid="B29">29</xref>).</p>
</sec>
<sec id="s8">
<title>Outcomes of periocular necrotizing fasciitis</title>
<p>PNF carries a more favorable prognosis than NF of other anatomic sites, with a reported mortality of 6-15% (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B18">18</xref>), compared to 20-30% for NF involving the head, neck, or extremity (<xref ref-type="bibr" rid="B7">7</xref>). Mortality is associated with delayed diagnosis (<xref ref-type="bibr" rid="B10">10</xref>), extension into cervical and thoracic compartments, and toxic shock syndrome (<xref ref-type="bibr" rid="B5">5</xref>). Septic shock has been identified as the strongest predictor of mortality, and was associated with facial involvement, visual impairment, and (albeit rare) Type 1 infections (<xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>Rates of orbital exenteration vary widely. One retrospective study documented exenteration in 4 of 7 cases (57%) and 2 of 58 cases (3%) (<xref ref-type="bibr" rid="B5">5</xref>), while a separate review reported exenteration in 7 of 94 cases (7.4%) (<xref ref-type="bibr" rid="B6">6</xref>). Although central nervous system complications have not been quantified in periorbital NF specifically, orbital necrotizing infections (a natural progression of PNF) have been associated with intracranial spread (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>), including meningitis, cavernous sinus thrombosis, and brain abscess, with reported mortality rates up to 14% (<xref ref-type="bibr" rid="B29">29</xref>).</p>
<p>Visual morbidity remains a chief cause of long-term disability. One PNF series reported blindness in 5 of 7 patients (71.4%) despite early surgical intervention, whereas another noted loss of vision in 13 of 94 cases (13.8%) (<xref ref-type="bibr" rid="B6">6</xref>). In addition to visual loss, soft tissue defects result in functional and cosmetic sequelae (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B10">10</xref>).</p>
</sec>
<sec id="s9" sec-type="discussion">
<title>Discussion</title>
<p>PNF remains a diagnostic and therapeutic challenge due to its subtle early manifestations, rapid progression, and potential visual morbidity. This review synthesizes evidence from primary clinical studies, systematic reviews, and narrative reviews to provide an&#xa0;updated perspective on contemporary diagnostic and management&#xa0;principles for PNF. <xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref> represents original clinical reports&#xa0;of&#xa0;periorbital or generalized-NF that provide anatomic characterization of infection sites, medical or surgical interventions, and documented outcomes.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Summary of primary literature on periorbital and generalized necrotizing fasciitis.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Study</th>
<th valign="middle" align="center">Study type</th>
<th valign="middle" align="center">Site(s) involved</th>
<th valign="middle" align="center">Intervention(s)</th>
<th valign="middle" align="center">Outcome(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">Kronish et&#xa0;al., 1991 (<xref ref-type="bibr" rid="B2">2</xref>)</td>
<td valign="middle" align="left">Case report (n=1) and literature review</td>
<td valign="middle" align="left">Periorbital</td>
<td valign="middle" align="left">Early surgical debridement, reconstruction, broad-spectrum IV antibiotics, and adjunct hyperbaric oxygen therapy</td>
<td valign="middle" align="left">Levator recovery with mild ptosis; no mortality.</td>
</tr>
<tr>
<td valign="middle" align="left">Elner et&#xa0;al., 2006 (<xref ref-type="bibr" rid="B5">5</xref>)</td>
<td valign="middle" align="left">Retrospective review<break/>(n=7)</td>
<td valign="middle" align="left">Periorbital, cheek, neck, chest, extremities</td>
<td valign="middle" align="left">Clinically aggressive surgical subcutaneous debridement with histopathologic evidence</td>
<td valign="middle" align="left">5 patients suffered loss of vision, 1 death due to septic shock.</td>
</tr>
<tr>
<td valign="middle" align="left">Yu et&#xa0;al., 2022 (<xref ref-type="bibr" rid="B12">12</xref>)</td>
<td valign="middle" align="left">Retrospective analysis (n=35)</td>
<td valign="middle" align="left">Lower extremities, sacrococcygeal area, chest</td>
<td valign="middle" align="left">Early and aggressive surgical debridement, VSD &#xb1; medium-thickness skin graft</td>
<td valign="middle" align="left">All patients survived (n=35), 22 underwent repeat debridement, 30-day average hospitalization, no reoccurrence observed.*</td>
</tr>
<tr>
<td valign="middle" align="left">Hadizamani et&#xa0;al., 2023 (<xref ref-type="bibr" rid="B10">10</xref>)</td>
<td valign="middle" align="left">Case report (n=1)</td>
<td valign="middle" align="left">Periorbital</td>
<td valign="middle" align="left">5 days of daily surgical debridement, outcomes prompting secondary surgical correction</td>
<td valign="middle" align="left">Recovery without need for skin grafts with ptosis, dermatochalasis, inferior lid ectropium (corrected).</td>
</tr>
<tr>
<td valign="middle" align="left">Oliver-Gutierrez et&#xa0;al., 2024 (<xref ref-type="bibr" rid="B13">13</xref>)</td>
<td valign="middle" align="left">Case series (n=9)</td>
<td valign="middle" align="left">Periorbital</td>
<td valign="middle" align="left">Surgical debridement, broad-spectrum IV antibiotics</td>
<td valign="middle" align="left">2 cases of toxic shock, with no fatalities. One exenteration. 5 cases with residual sequelae (ptosis, lagophthalmos, exposure keratopathy, etc.). Final BCVA in preserved eyes 0.1&#x2013;1.0.</td>
</tr>
<tr>
<td valign="middle" align="left">Saldana et&#xa0;al., 2010 (<xref ref-type="bibr" rid="B23">23</xref>)</td>
<td valign="middle" align="left">Case report (n=5)</td>
<td valign="middle" align="left">Periorbital</td>
<td valign="middle" align="left">CT-guided surgical debridement</td>
<td valign="middle" align="left">No fatalities. 4 patients had minimal surgical debridement to the surface muscle. 4 patients underwent delayed reconstruction.</td>
</tr>
<tr>
<td valign="middle" align="left">Hopkins et&#xa0;al., 2025 (<xref ref-type="bibr" rid="B31">31</xref>)</td>
<td valign="middle" align="left">Case series (n=5)</td>
<td valign="middle" align="left">Periorbital</td>
<td valign="middle" align="left">Early IV antibiotics and urgent surgical debridement</td>
<td valign="middle" align="left">All patients underwent up to 4 debridements. No fatalities. 2 cases of post-septal involvement. 3 cases of orbital compartment syndrome, with two resulting in VA of NPL. 4 cases of lagophthalmos, 2 cases of exposure keratopathy, 1 case of ectropion. Use of LRINEC unreliable.</td>
</tr>
<tr>
<td valign="middle" align="left">Tambe et&#xa0;al., 2012 (<xref ref-type="bibr" rid="B32">32</xref>)</td>
<td valign="middle" align="left">Case series (n=11)</td>
<td valign="middle" align="left">Periorbital, face, neck, chest</td>
<td valign="middle" align="left">Broad-spectrum IV antibiotics and surgical debridement</td>
<td valign="middle" align="left">One fatality due to systemic shock and multiorgan failure. One case of lost site in the affected eye due to CRAO. Remaining 9 cases preserved vision with acceptable functional and cosmetic results. LRINEC score did not correlate with PNF severity.</td>
</tr>
<tr>
<td valign="middle" align="left">Rajak et&#xa0;al., 2016 (<xref ref-type="bibr" rid="B27">27</xref>)</td>
<td valign="middle" align="left">Case series (n=29)</td>
<td valign="middle" align="left">Periorbital, face, neck, scalp.</td>
<td valign="middle" align="left">IV antibiotics with cautious observation, surgical debridement</td>
<td valign="middle" align="left">Up to 5 tissue debridements to control disease in 23 patients. One fatality prior to debridement. One case of intracranial spread. 6 cases of systemic shock. Visual loss occurred in 4 eyes of 4 patients.</td>
</tr>
<tr>
<td valign="middle" align="left">Mutamba et&#xa0;al. (2013) (<xref ref-type="bibr" rid="B26">26</xref>)</td>
<td valign="middle" align="left">Case series (n=3)</td>
<td valign="middle" align="left">Periorbital</td>
<td valign="middle" align="left">IV or oral antibiotics, delayed &#x201c;elective&#x201d; debridement</td>
<td valign="middle" align="left">Debridement underwent in all 3 cases. All 3 cases underwent reconstructive skin grafting. All achieved satisfactory cosmetic result. One case of lacrimal symptoms due to static eye. One case&#x2019;s VA noted to improve from HM at presentation to 6/9.</td>
</tr>
<tr>
<td valign="middle" align="left">Hu et&#xa0;al., 2008 (<xref ref-type="bibr" rid="B18">18</xref>)</td>
<td valign="middle" align="left">Case report (n=1)</td>
<td valign="middle" align="left">Periorbital</td>
<td valign="middle" align="left">High dose IV antibiotics, bedside debridement</td>
<td valign="middle" align="left">Post-antibiotics: No necrotic progression, gradual improvement of affected area. Post-debridement: Return of EOMs, VA at HM.</td>
</tr>
<tr>
<td valign="middle" align="left">I&#x15f;ik et&#xa0;al., 2025 (<xref ref-type="bibr" rid="B20">20</xref>)</td>
<td valign="middle" align="left">Case report (n=1)</td>
<td valign="middle" align="left">Periorbital</td>
<td valign="middle" align="left">Broad-spectrum IV antibiotics, IVIG, surgical drainage/fasciotomy, and hypochlorous acid irrigation</td>
<td valign="middle" align="left">Resolved without sequelae.</td>
</tr>
<tr>
<td valign="middle" align="left">Crew et&#xa0;al., 2016 (<xref ref-type="bibr" rid="B11">11</xref>)</td>
<td valign="middle" align="left">Case series (n=6)</td>
<td valign="middle" align="left">Extremities, trunk, genitalia</td>
<td valign="middle" align="left">Flow-through 0.01% HCl via NPWT as adjunct to surgical debridement and antibiotics &#xb1; hyperbaric oxygen therapy</td>
<td valign="middle" align="left">All patients achieved infection resolution and wound healing within 2&#x2013;8 weeks; no mortality or recurrence reported; HOCl with NPWT facilitated rapid recovery and improved cosmesis.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>NPWT, negative pressure wound therapy; BCVA, best corrected visual acuity; VSD, vacuum sealing drainage; EOM, extraocular movements; VA, visual acuity; NPL, no perception of light; HM, hand motion; IVIG, IV immunoglobulin</p></fn>
<fn>
<p>*Among re-examined patients at one year follow-up</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Early recognition of PNF is critical, as prompt surgical debridement remains as the foundation of management. However, PNF may progress rapidly before cutaneous necrosis becomes apparent, and symptoms such as disproportionate pain, systemic toxicity, or rapidly expanding edema warrant urgent imaging to confirm fascial involvement (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B22">22</xref>). CT or MRI imaging is also indicated to differentiate PNF from pre-septal, orbital cellulitis, myonecrosis, and other masquerades (<xref ref-type="bibr" rid="B6">6</xref>). Key findings on CT include soft tissue gas, superficial fascial thickening or nonenhancement (<xref ref-type="bibr" rid="B6">6</xref>), fluid tracking along fascial planes (<xref ref-type="bibr" rid="B5">5</xref>), loss of normal fat planes, and edema extending beyond the region of visible skin changes (<xref ref-type="bibr" rid="B6">6</xref>). One PNF case report demonstrated CT alone was sufficient to guide surgical debridement (<xref ref-type="bibr" rid="B21">21</xref>). MRI is more sensitive for early disease and superior delineation of infection extent (<xref ref-type="bibr" rid="B22">22</xref>). Characteristic findings include T2-weighted hyperintensity of the deep fascia and post-contrast T1-weighted fascial nonenhancement suggestive of necrosis, muscle edema, or myonecrosis.</p>
<p>While the LRINEC score may support early risk stratification in NF, its applicability in PN is limited. The score has not been found to correlate with PNF severity (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>) and may not account for neutropenic or immunocompromised patients. Accordingly, LRINEC should be interpreted only as an adjunctive tool, and low scores should not delay surgical intervention when clinical suspicion remains high.</p>
<p>The timing and extent of debridement remain among the most debated aspects of PNF management. Early and aggressive debridement improves source control and reduces mortality, but also carries substantial functional and cosmetic morbidity (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B10">10</xref>). The periorbital region&#x2019;s rich vascularity simultaneously protects against disease progression and complicates management. Extensive arterial anastomoses of the superior and inferior superficial arcades provide robust perfusion that enhance immune cell trafficking essential for localized control of infection and may explain the reported success of conservative management with intravenous antibiotics in select patients with involvement limited to the eyelids without systemic comprimise (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B18">18</xref>). Several case series support selective debridement strategies that preserve junctional tissue adjacent to viable skin, allowing auto-demarcation and granulation in clinically stable patients. (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>) Thus, management often involves a nuanced balance between aggressive source control and tissue preservation, combining surgery and antimicrobial therapy based on disease severity and progression. Nevertheless, conservative therapy requires a high index of suspicion (<xref ref-type="bibr" rid="B6">6</xref>) and close monitoring.</p>
<p>The same vascularity that may protect against progression can also mask disease severity. Viable-appearing skin may overlie necrotic subcutaneous tissue while local microvascular thrombosis limits antibiotic penetration. Clinical indicators such as disproportionate pain, rapid edematous progression, cyanotic-violaceous discoloration, cutaneous anesthesia, bullae necrosis, and systemic toxicity should heighten concern for advancing necrosis (<xref ref-type="bibr" rid="B6">6</xref>). Early surgical debridement is indicated with evidence of systemic toxicity and deep fascial or orbital involvement (including extension beyond the orbital septum and loss of tissue plane integrity), rapid progression, or gaseous formation on imaging (<xref ref-type="bibr" rid="B5">5</xref>). These features signal deeper necrosis and prompt urgent surgical consultation, as delays beyond 24 hours can markedly worsen prognosis and tissue destruction (<xref ref-type="bibr" rid="B6">6</xref>). Consequently, debridement remains a cornerstone of therapy and is often repeated until viable tissue margins are achieved (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B12">12</xref>). In contrast to NF at other anatomical sites, PNF may permit a less aggressive surgical approach due to robust regional vascularity and the high functional cost of tissue loss.</p>
<p>Adjunctive treatments, such as topical HOCl irrigation (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B33">33</xref>) or NPWT (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B34">34</xref>) may enhance local infection control while minimizing surgical morbidity. A generalized-NF case series supported the use 0.01% pure HOCl applied through a flow-through NPWT at high frequency every four to six hours, with five minutes of treatment time per cycle (<xref ref-type="bibr" rid="B11">11</xref>). A pediatric PNF case report irrigated and performed drainage changes every two hours (<xref ref-type="bibr" rid="B21">21</xref>). This regimen is justified by HOCl&#x2019;s rapid consumption of protein-rich necrotic tissue and neutralization of streptococcal superantigens, staphylococcal cytotoxins, and anaerobic proteases (<xref ref-type="bibr" rid="B33">33</xref>). Therapy is continued until acute inflammation resolves, generally over one to three weeks (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B20">20</xref>). As the periocular region is difficult to seal and more vulnerable to pressure-related injury, adapting this HOCl-NPWT technique to PNF would require modified ophthalmic interfaces and further study. In contrast, general wound care protocols, such as diabetic-venous foot ulcers and postoperative wounds, employ once-daily HOCl with treatment times of 15 to 20 minutes (<xref ref-type="bibr" rid="B33">33</xref>), reflecting lower rates of toxin production and necrotic load.</p>
<p>If standard PNF treatments fail or clinical features are atypical, alternative diagnoses must be considered. Type IV fungal NF should be suspected in diabetic or immunocompromised patients. Sweet&#x2019;s syndrome (SS) represents a critical diagnostic pitfall. SS presents with painful, erythematous plaques or nodules, fever, and neutrophilia and its necrotizing variant can closely mimic PNF (<xref ref-type="bibr" rid="B25">25</xref>). Histopathology distinguishes SS by demonstrating dense neutrophilic infiltrate without microorganisms or vasculitis (<xref ref-type="bibr" rid="B25">25</xref>,&#xa0;<xref ref-type="bibr" rid="B35">35</xref>). Misdiagnosis has grave consequences: PNF typically requires urgent surgical debridement and antibiotics, whereas SS responds to systemic corticosteroids. Inappropriate debridement in SS results in pathergy (<xref ref-type="bibr" rid="B35">35</xref>). Accordingly, in addition to early use of imaging when uncertainty persists, prompt biopsy is essential.</p>
<p>Current research gaps remain. These include advanced PNF-NPWT wound dressings and standardized criteria to guide conservative versus surgical management (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B10">10</xref>). Robust comparative data on adjunctive therapies such as hyperbaric oxygen, IVIG, or flow-through HOCl are also lacking (<xref ref-type="bibr" rid="B11">11</xref>). Additionally, further investigation in reliable serologic biomarkers capable of distinguishing PNF from orbital cellulitis or Sweet&#x2019;s syndrome is warranted (<xref ref-type="bibr" rid="B24">24</xref>).</p>
</sec>
</body>
<back>
<sec id="s10" sec-type="author-contributions">
<title>Author contributions</title>
<p>ZS: Writing &#x2013; original draft, Investigation, Writing &#x2013; review &amp; editing, Data curation. HK: Writing &#x2013; review &amp; editing. AH: Writing &#x2013; review &amp; editing. AM: Supervision, Writing &#x2013; review &amp; editing, Conceptualization.</p></sec>
<sec id="s12" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s13" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec>
<sec id="s14" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shindo</surname> <given-names>ML</given-names></name>
<name><surname>Nalbone</surname> <given-names>VP</given-names></name>
<name><surname>Dougherty</surname> <given-names>WR</given-names></name>
</person-group>. 
<article-title>Necrotizing fasciitis of the face</article-title>. <source>Laryngoscope</source>. (<year>1997</year>) <volume>107</volume>:<page-range>1071&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/00005537-199708000-00013</pub-id>, PMID: <pub-id pub-id-type="pmid">9261011</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kronish</surname> <given-names>JW</given-names></name>
<name><surname>McLeish</surname> <given-names>WM</given-names></name>
</person-group>. 
<article-title>Eyelid necrosis and periorbital necrotizing fasciitis. Report of a case and review of the literature</article-title>. <source>Ophthalmology</source>. (<year>1991</year>) <volume>98</volume>:<page-range>92&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0161-6420(91)32334-0</pub-id>, PMID: <pub-id pub-id-type="pmid">2023741</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Factor</surname> <given-names>SH</given-names></name>
<name><surname>Levine</surname> <given-names>OS</given-names></name>
<name><surname>Schwartz</surname> <given-names>B</given-names></name>
<name><surname>Harrison</surname> <given-names>L</given-names></name>
<name><surname>Farley</surname> <given-names>MM</given-names></name>
<name><surname>McGeer</surname> <given-names>A</given-names></name>
<etal/>
</person-group>. 
<article-title>Invasive group A streptococcal disease: risk factors for adults</article-title>. <source>Emerg Infect Dis</source>. (<year>2003</year>) <volume>9</volume>:<page-range>970&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3201/eid0908.020745</pub-id>, PMID: <pub-id pub-id-type="pmid">12967496</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Roje</surname> <given-names>Z</given-names></name>
<name><surname>Roje</surname> <given-names>Z</given-names></name>
<name><surname>Mati&#x107;</surname> <given-names>D</given-names></name>
<name><surname>Librenjak</surname> <given-names>D</given-names></name>
<name><surname>Dokuzovi&#x107;</surname> <given-names>S</given-names></name>
<name><surname>Varvodi&#x107;</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>Necrotizing fasciitis: literature review of contemporary strategies for diagnosing and management with three case reports: torso, abdominal wall, upper and lower limbs</article-title>. <source>World J Emerg Surg</source>. (<year>2011</year>) <volume>6</volume>:<elocation-id>46</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1749-7922-6-46</pub-id>, PMID: <pub-id pub-id-type="pmid">22196774</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Elner</surname> <given-names>VM</given-names></name>
<name><surname>Demirci</surname> <given-names>H</given-names></name>
<name><surname>Nerad</surname> <given-names>JA</given-names></name>
<name><surname>Hassan</surname> <given-names>AS</given-names></name>
</person-group>. 
<article-title>Periocular necrotizing fasciitis with visual loss pathogenesis and treatment</article-title>. <source>Ophthalmology</source>. (<year>2006</year>) <volume>113</volume>:<page-range>2338&#x2013;45</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ophtha.2006.06.037</pub-id>, PMID: <pub-id pub-id-type="pmid">16996594</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Amrith</surname> <given-names>S</given-names></name>
<name><surname>Hosdurga Pai</surname> <given-names>V</given-names></name>
<name><surname>Ling</surname> <given-names>WW</given-names></name>
</person-group>. 
<article-title>Periorbital necrotizing fasciitis &#x2013; a review</article-title>. <source>Acta Ophthalmol</source>. (<year>2013</year>) <volume>91</volume>:<fpage>596</fpage>&#x2013;<lpage>603</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1755-3768.2012.02420.x</pub-id>, PMID: <pub-id pub-id-type="pmid">22520175</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lazzeri</surname> <given-names>D</given-names></name>
<name><surname>Lazzeri</surname> <given-names>S</given-names></name>
<name><surname>Figus</surname> <given-names>M</given-names></name>
<name><surname>Tascini</surname> <given-names>C</given-names></name>
<name><surname>Bocci</surname> <given-names>G</given-names></name>
<name><surname>Colizzi</surname> <given-names>L</given-names></name>
<etal/>
</person-group>. 
<article-title>Periorbital necrotising fasciitis</article-title>. <source>Br J Ophthalmol</source>. (<year>2010</year>) <volume>94</volume>:<page-range>1577&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bjo.2009.167486</pub-id>, PMID: <pub-id pub-id-type="pmid">19897473</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Prendiville</surname> <given-names>KJ</given-names></name>
<name><surname>Bath</surname> <given-names>PE</given-names></name>
</person-group>. 
<article-title>Lateral cantholysis and eyelid necrosis secondary to Pseudomonas aeruginosa</article-title>. <source>Ann Ophthalmol</source>. (<year>1988</year>) <volume>20</volume>:<page-range>193&#x2013;5</page-range>., PMID: <pub-id pub-id-type="pmid">3408085</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Scheepers</surname> <given-names>MA</given-names></name>
<name><surname>Keel</surname> <given-names>S</given-names></name>
<name><surname>Michaelides</surname> <given-names>M</given-names></name>
</person-group>. 
<article-title>Bilateral necrotising fasciitis of the ocular adnexa secondary to Pseudomonas aeruginosa septicaemia in a HIV-positive child</article-title>. <source>Orbit</source>. (<year>2010</year>) <volume>29</volume>:<page-range>63&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3109/01676830903258847</pub-id>, PMID: <pub-id pub-id-type="pmid">20302416</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hadizamani</surname> <given-names>Y</given-names></name>
<name><surname>Anastasi</surname> <given-names>S</given-names></name>
<name><surname>Schori</surname> <given-names>A</given-names></name>
<name><surname>Lucas</surname> <given-names>R</given-names></name>
<name><surname>Garweg</surname> <given-names>JG</given-names></name>
<name><surname>Hamacher</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>Pathophysiological considerations in periorbital necrotizing fasciitis: A case report</article-title>. <source>Ocul Immunol Inflamm</source>. (<year>2023</year>) <volume>31</volume>:<page-range>468&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/09273948.2022.2032190</pub-id>, PMID: <pub-id pub-id-type="pmid">35404751</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Crew</surname> <given-names>JR</given-names></name>
<name><surname>Thibodeaux</surname> <given-names>KT</given-names></name>
<name><surname>Speyrer</surname> <given-names>MS</given-names></name>
<name><surname>Gauto</surname> <given-names>AR</given-names></name>
<name><surname>Shiau</surname> <given-names>T</given-names></name>
<name><surname>Pang</surname> <given-names>L</given-names></name>
<etal/>
</person-group>. 
<article-title>Flow-through instillation of hypochlorous acid in the treatment of necrotizing fasciitis</article-title>. <source>Wounds</source>. (<year>2016</year>) <volume>28</volume>:<page-range>40&#x2013;7</page-range>., PMID: <pub-id pub-id-type="pmid">26891136</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yu</surname> <given-names>X</given-names></name>
<name><surname>Guo</surname> <given-names>Z</given-names></name>
<name><surname>Zhang</surname> <given-names>M</given-names></name>
<name><surname>Fu</surname> <given-names>Q</given-names></name>
<name><surname>Zhou</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>Clinical analysis of diagnosis and treatment of necrotizing fasciitis</article-title>. <source>Eur J Inflammation</source>. (<year>2022</year>) <volume>10</volume>:<page-range>1&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/1721727X221141822</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Oliver-Gutierrez</surname> <given-names>D</given-names></name>
<name><surname>van der Veen</surname> <given-names>RLP</given-names></name>
<name><surname>Ros-Sanchez</surname> <given-names>E</given-names></name>
<name><surname>Segura-Duch</surname> <given-names>G</given-names></name>
<name><surname>Alonso</surname> <given-names>T</given-names></name>
<name><surname>Herranz-Cabarcos</surname> <given-names>A</given-names></name>
<etal/>
</person-group>. 
<article-title>Periorbital necrotizing fasciitis: clinical perspectives on nine cases</article-title>. <source>Eur J Clin Microbiol Infect Dis</source>. (<year>2024</year>) <volume>43</volume>:<page-range>2053&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10096-024-04908-6</pub-id>, PMID: <pub-id pub-id-type="pmid">39085512</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Harrison</surname> <given-names>WD</given-names></name>
<name><surname>Kapoor</surname> <given-names>B</given-names></name>
</person-group>. 
<article-title>Necrotizing soft tissue infection: principles of diagnosis and management</article-title>. <source>Orthop Trauma</source>. (<year>2016</year>) <volume>30</volume>:<page-range>223&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mporth.2016.05.001</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Paz Maya</surname> <given-names>S</given-names></name>
<name><surname>Dualde Beltr&#xe1;n</surname> <given-names>D</given-names></name>
<name><surname>Lemercier</surname> <given-names>P</given-names></name>
<name><surname>Leiva-Salinas</surname> <given-names>C</given-names></name>
</person-group>. 
<article-title>Necrotizing fasciitis: an urgent diagnosis</article-title>. <source>Skeletal Radiol</source>. (<year>2014</year>) <volume>43</volume>:<page-range>577&#x2013;89</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00256-013-1813-2</pub-id>, PMID: <pub-id pub-id-type="pmid">24469151</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kuo</surname> <given-names>YL</given-names></name>
<name><surname>Shieh</surname> <given-names>SJ</given-names></name>
<name><surname>Chiu</surname> <given-names>HY</given-names></name>
<name><surname>Lee</surname> <given-names>JW</given-names></name>
</person-group>. 
<article-title>Necrotizing fasciitis caused by Vibrio vulnificus: epidemiology, clinical findings, treatment and prevention</article-title>. <source>Eur J Clin Microbiol Infect Dis</source>. (<year>2007</year>) <volume>26</volume>:<page-range>785&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10096-007-0358-5</pub-id>, PMID: <pub-id pub-id-type="pmid">17674061</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hussain</surname> <given-names>H</given-names></name>
<name><surname>Fadel</surname> <given-names>A</given-names></name>
<name><surname>Garcia</surname> <given-names>E</given-names></name>
<name><surname>Hernandez</surname> <given-names>RJ</given-names></name>
<name><surname>Saadoon</surname> <given-names>ZF</given-names></name>
<name><surname>Naseer</surname> <given-names>L</given-names></name>
<etal/>
</person-group>. 
<article-title>Clostridial myonecrosis: A comprehensive review of toxin pathophysiology and management strategies</article-title>. <source>Microorganisms</source>. (<year>2024</year>) <volume>12</volume>:<elocation-id>1464</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/microorganisms12071464</pub-id>, PMID: <pub-id pub-id-type="pmid">39065232</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hu</surname> <given-names>V</given-names></name>
<name><surname>Turner</surname> <given-names>S</given-names></name>
<name><surname>Robinson</surname> <given-names>F</given-names></name>
</person-group>. 
<article-title>Non-progressive periorbital necrotising fasciitis</article-title>. <source>Orbit</source>. (<year>2008</year>) <volume>27</volume>:<fpage>59</fpage>&#x2013;<lpage>62</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/01676830601174692</pub-id>, PMID: <pub-id pub-id-type="pmid">18307150</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lancerotto</surname> <given-names>L</given-names></name>
<name><surname>Tocco</surname> <given-names>I</given-names></name>
<name><surname>Salmaso</surname> <given-names>R</given-names></name>
<name><surname>Vindigni</surname> <given-names>V</given-names></name>
<name><surname>Bassetto</surname> <given-names>F</given-names></name>
</person-group>. 
<article-title>Necrotizing fasciitis: classification, diagnosis, and management</article-title>. <source>J Trauma Acute Care Surg</source>. (<year>2012</year>) <volume>72</volume>:<page-range>560&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/TA.0b013e318232a6b3</pub-id>, PMID: <pub-id pub-id-type="pmid">22491537</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>I&#x15f;ik</surname> <given-names>DI</given-names></name>
<name><surname>Yilmaz</surname> <given-names>S</given-names></name>
<name><surname>Canizci Erdemli</surname> <given-names>P</given-names></name>
<name><surname>B&#xfc;y&#xfc;kta&#x15f; Ayta&#xe7;</surname> <given-names>D</given-names></name>
<name><surname>Abaci &#xc7;apar</surname> <given-names>MC</given-names></name>
<name><surname>Ya&#x15f;ar</surname> <given-names>HC</given-names></name>
<etal/>
</person-group>. 
<article-title>Periorbital necrotizing fasciitis in a child without a predisposing factor</article-title>. <source>Pediatr Infect Dis J</source>. (<year>2025</year>) <volume>44</volume>:<page-range>e430&#x2013;1</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/INF.0000000000004895</pub-id>, PMID: <pub-id pub-id-type="pmid">40444997</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wong</surname> <given-names>CH</given-names></name>
<name><surname>Khin</surname> <given-names>LW</given-names></name>
<name><surname>Heng</surname> <given-names>KS</given-names></name>
<name><surname>Tan</surname> <given-names>KC</given-names></name>
<name><surname>Low</surname> <given-names>CO</given-names></name>
</person-group>. 
<article-title>The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections</article-title>. <source>Crit Care Med</source>. (<year>2004</year>) <volume>32</volume>:<page-range>1535&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/01.ccm.0000129486.35458.7d</pub-id>, PMID: <pub-id pub-id-type="pmid">15241098</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wysoki</surname> <given-names>MG</given-names></name>
<name><surname>Santora</surname> <given-names>TA</given-names></name>
<name><surname>Shah</surname> <given-names>RM</given-names></name>
<name><surname>Friedman</surname> <given-names>AC</given-names></name>
</person-group>. 
<article-title>Necrotizing fasciitis: CT characteristics</article-title>. <source>Radiology</source>. (<year>1997</year>) <volume>203</volume>:<page-range>859&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiology.203.3.9169717</pub-id>, PMID: <pub-id pub-id-type="pmid">9169717</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Saldana</surname> <given-names>M</given-names></name>
<name><surname>Gupta</surname> <given-names>D</given-names></name>
<name><surname>Khandwala</surname> <given-names>M</given-names></name>
<name><surname>Weir</surname> <given-names>R</given-names></name>
<name><surname>Beigi</surname> <given-names>B</given-names></name>
</person-group>. 
<article-title>Periorbital necrotizing fasciitis: outcomes using a CT-guided surgical debridement approach</article-title>. <source>Eur J Ophthalmol</source>. (<year>2010</year>) <volume>20</volume>:<page-range>209&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/112067211002000129</pub-id>, PMID: <pub-id pub-id-type="pmid">19882528</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wladis</surname> <given-names>EJ</given-names></name>
<name><surname>LeSage</surname> <given-names>C</given-names></name>
<name><surname>Paez</surname> <given-names>M</given-names></name>
<name><surname>Grube</surname> <given-names>JG</given-names></name>
<name><surname>Pokabla</surname> <given-names>MJ</given-names></name>
<name><surname>Adam</surname> <given-names>AP</given-names></name>
</person-group>. 
<article-title>Derived neutrophil-to-lymphocyte and neutrophil-to-platelet ratios distinguish sinusitis-related orbital cellulitis from periorbital necrotizing fasciitis</article-title>. <source>Ophthalmic Plast Reconstr Surg</source>. (<year>2025</year>) <volume>41</volume>:<page-range>401&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/IOP.0000000000002864</pub-id>, PMID: <pub-id pub-id-type="pmid">39714285</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Watson</surname> <given-names>SL</given-names></name>
<name><surname>Kuo</surname> <given-names>A</given-names></name>
<name><surname>Kishi</surname> <given-names>SH</given-names></name>
<name><surname>Fat</surname> <given-names>MN</given-names></name>
<name><surname>Boxrud</surname> <given-names>CA</given-names></name>
</person-group>. 
<article-title>Periorbital necrotizing sweet's syndrome: A case report</article-title>. <source>Ophthalmic Plast Reconstr Surg</source>. (<year>2023</year>) <volume>39</volume>:<page-range>e197&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/IOP.0000000000002463</pub-id>, PMID: <pub-id pub-id-type="pmid">37486325</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mutamba</surname> <given-names>A</given-names></name>
<name><surname>Verity</surname> <given-names>DH</given-names></name>
<name><surname>Rose</surname> <given-names>GE</given-names></name>
</person-group>. 
<article-title>'Stalled' periocular necrotising fasciitis: early effective treatment or host genetic determinants</article-title>? <source>Eye (Lond)</source>. (<year>2013</year>) <volume>27</volume>:<page-range>432&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/eye.2012.285</pub-id>, PMID: <pub-id pub-id-type="pmid">23412558</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rajak</surname> <given-names>SN</given-names></name>
<name><surname>Figueira</surname> <given-names>EC</given-names></name>
<name><surname>Haridas</surname> <given-names>AS</given-names></name>
<name><surname>Satchi</surname> <given-names>K</given-names></name>
<name><surname>Uddin</surname> <given-names>JM</given-names></name>
<name><surname>McNab</surname> <given-names>AA</given-names></name>
<etal/>
</person-group>. 
<article-title>Periocular necrotising fasciitis: a multicentre case series</article-title>. <source>Br J Ophthalmol</source>. (<year>2016</year>) <volume>100</volume>:<page-range>1517&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bjophthalmol-2015-307445</pub-id>, PMID: <pub-id pub-id-type="pmid">26837505</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zadjali</surname> <given-names>FA</given-names></name>
<name><surname>Hua</surname> <given-names>N</given-names></name>
<name><surname>Tohm&#xe9;</surname> <given-names>A</given-names></name>
<name><surname>Alsaffar</surname> <given-names>H</given-names></name>
<name><surname>Johnson-Obaseki</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>Necrotizing fasciitis of the head and neck in era of COVID-19: a single-institution experience</article-title>. <source>IJID Reg</source>. (<year>2024</year>) <volume>12</volume>:<elocation-id>100413</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijregi.2024.100413</pub-id>, PMID: <pub-id pub-id-type="pmid">39263679</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sankaranarayanan</surname> <given-names>S</given-names></name>
<name><surname>Spielman</surname> <given-names>AF</given-names></name>
<name><surname>Lessard</surname> <given-names>AS</given-names></name>
<name><surname>Husain</surname> <given-names>T</given-names></name>
</person-group>. 
<article-title>Upper extremity necrotizing fasciitis in a Covid-19 patient</article-title>. <source>Case Rep Plast Surg Handb Surg</source>. (<year>2022</year>) <volume>9</volume>:<fpage>46</fpage>&#x2013;<lpage>51</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/23320885.2022.2028550</pub-id>, PMID: <pub-id pub-id-type="pmid">35083369</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pakdel</surname> <given-names>F</given-names></name>
<name><surname>Salehi</surname> <given-names>M</given-names></name>
<name><surname>Darazam</surname> <given-names>IA</given-names></name>
<name><surname>Salahshour</surname> <given-names>F</given-names></name>
<name><surname>Khalili</surname> <given-names>H</given-names></name>
<name><surname>Shafaati</surname> <given-names>M</given-names></name>
<etal/>
</person-group>. 
<article-title>Necrotizing orbital infections: A comprehensive review</article-title>. <source>Saudi J Ophthalmol</source>. (<year>2025</year>) <volume>39</volume>:<page-range>128&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4103/sjopt.sjopt_87_25</pub-id>, PMID: <pub-id pub-id-type="pmid">40642363</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hopkins</surname> <given-names>A</given-names></name>
<name><surname>Ng</surname> <given-names>JKY</given-names></name>
<name><surname>Ku</surname> <given-names>JY</given-names></name>
<name><surname>Bull</surname> <given-names>A</given-names></name>
<name><surname>Pilson</surname> <given-names>Q</given-names></name>
<name><surname>Cook</surname> <given-names>A</given-names></name>
</person-group>. 
<article-title>Periorbital necrotizing fasciitis: the Manchester experience</article-title>. <source>BMC Ophthalmol</source>. (<year>2025</year>) <volume>25</volume>:<fpage>221</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12886-025-04062-3</pub-id>, PMID: <pub-id pub-id-type="pmid">40247190</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tambe</surname> <given-names>K</given-names></name>
<name><surname>Tripathi</surname> <given-names>A</given-names></name>
<name><surname>Burns</surname> <given-names>J</given-names></name>
<name><surname>Sampath</surname> <given-names>R</given-names></name>
</person-group>. 
<article-title>Multidisciplinary management of periocular necrotising fasciitis: a series of 11 patients</article-title>. <source>Eye (Lond)</source>. (<year>2012</year>) <volume>26</volume>:<page-range>463&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/eye.2011.241</pub-id>, PMID: <pub-id pub-id-type="pmid">22157919</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Armstrong</surname> <given-names>DG</given-names></name>
<name><surname>Bohn</surname> <given-names>G</given-names></name>
<name><surname>Glat</surname> <given-names>P</given-names></name>
<name><surname>Kavros</surname> <given-names>SJ</given-names></name>
<name><surname>Kirsner</surname> <given-names>R</given-names></name>
<name><surname>Snyder</surname> <given-names>R</given-names></name>
<etal/>
</person-group>. 
<article-title>Expert recommendations for the use of hypochlorous solution: science and clinical application</article-title>. <source>Ostomy Wound Manage</source>. (<year>2015</year>) <volume>61</volume>:<fpage>S2</fpage>&#x2013;<lpage>S19</lpage>., PMID: <pub-id pub-id-type="pmid">28692424</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Prasanna Kumar</surname> <given-names>S</given-names></name>
<name><surname>Ravikumar</surname> <given-names>A</given-names></name>
<name><surname>Somu</surname> <given-names>L</given-names></name>
</person-group>. 
<article-title>Fungal necrotizing fasciitis of the head and neck in 3 patients with uncontrolled diabetes</article-title>. <source>Ear Nose Throat J</source>. (<year>2014</year>) <volume>93</volume>:<page-range>E18&#x2013;21</page-range>., PMID: <pub-id pub-id-type="pmid">24652565</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Vongsachang</surname> <given-names>H</given-names></name>
<name><surname>Chiou</surname> <given-names>CA</given-names></name>
<name><surname>Azad</surname> <given-names>AD</given-names></name>
<name><surname>Lin</surname> <given-names>LY</given-names></name>
<name><surname>Yoon</surname> <given-names>MK</given-names></name>
<name><surname>Lefebvre</surname> <given-names>DR</given-names></name>
<etal/>
</person-group>. 
<article-title>Periorbital necrotizing sweet syndrome: A report of two cases mimicking necrotizing soft tissue infections</article-title>. <source>Am J Ophthalmol Case Rep</source>. (<year>2024</year>) <volume>34</volume>:<elocation-id>102033</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ajoc.2024.102033</pub-id>, PMID: <pub-id pub-id-type="pmid">38487334</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2142351">Farzad Pakdel</ext-link>, Tehran University of Medical Sciences, Iran</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3170376">Davin Ashraf</ext-link>, Oregon Health &amp; Science University, United States</p></fn>
</fn-group>
</back>
</article>